Pain is a complex and multifaceted condition that serves as the body’s warning system, signaling potential or actual tissue damage. It can be acute—arising suddenly and typically resolving with healing—or chronic, persisting for weeks, months, or even years, often without a clear cause. Chronic pain affects over 1.5 billion people globally and remains one of the leading causes of disability worldwide. The pain management market is valued at over $80 billion globally, with significant growth projected due to the rising prevalence of conditions such as arthritis, cancer, neuropathy, and postoperative pain. Current treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, anticonvulsants, antidepressants, and interventional approaches such as nerve blocks and spinal cord stimulation. However, many of these options are associated with limited efficacy or serious side effects, including dependency and tolerance in the case of opioids. There is a critical need for safer, more effective therapies that address both the symptoms and underlying mechanisms of chronic pain. With ongoing advancements in neuroscience and drug development, the field presents significant opportunities for innovation in non-opioid and targeted pain relief solutions.
Zebrafish Model: Utilizing a validated assay in 5 dpf larvae to screen for compounds with analgesic (pain-relieving) properties